^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PM3023

    i
    Other names: PM3023, CLDN18.2 CAB-T
    Associations

    News

    Trials
    Company:
    Biotheus
    Drug class:
    CLDN18.2 inhibitor, T-cell stimulant
    Related drugs:
    Associations

    News

    Trials
    2years
    Claudin18.2-targeting CAB-T cells have superior safety over traditional CAR-T, while maintaining potent in vivo anti-tumor efficacy (SITC 2022)
    CLDN18.2-CAB-T is currently undergoing an investigator-initiated trial to test its safety and efficacy for subjects with CLDN18.2+ solid tumors. Ethics Approval All mice were maintained under specified pathogen-free conditions, and all studies were approved by the Animal Care and Use Committee of HUST-Suzhou Institute for Brainsmatics.
    Preclinical • IO biomarker
    |
    CLDN18 (Claudin 18) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2) • CLDN8 (Claudin 8)
    |
    CLDN18.2 positive
    |
    PM3023